Aquestive Therapeutics (NASDAQ:AQST) is up 13% premarket on light volume on the heels of its announcement of preliminary Q4 and 2019 revenues of ~$16M and ~$52M, respectively, both above consensus.
Cash and equivalents at year-end: ~$49M.
Final Q4 and 2019 results will be released on March 12.
2020 guidance: Revenues: $35M – 45M (below consensus of ~$57M). Non-GAAP gross margin: 70 – 75%. Non-GAAP EBITDA loss: ($70M – 65M). Cash consumption: ($70M – 65M).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.